Critical Contrast: QHSLab (OTCMKTS:USAQ) vs. Solana (NASDAQ:HSDT)

Solana (NASDAQ:HSDT) and QHSLab (OTCMKTS:USAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Solana and QHSLab, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	1	1	1	2.50
QHSLab	0	0	0	0	0.00

Solana presently has a consensus target price of $3.50, suggesting a potential upside of 95.53%. Given Solana’s stronger consensus rating and higher probable upside, analysts plainly believe Solana is more favorable than QHSLab.

Risk and Volatility

Solana has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, QHSLab has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Valuation and Earnings

This table compares Solana and QHSLab”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02 million	17.36	-$40.89 million	($109.67)	-0.02
QHSLab	$2.69 million	1.11	$460,000.00	$0.03	8.83

QHSLab has lower revenue, but higher earnings than Solana. Solana is trading at a lower price-to-earnings ratio than QHSLab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Solana and QHSLab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-1,427.15%	-67.57%	-24.09%
QHSLab	15.60%	-27.74%	-6.98%

Institutional & Insider Ownership

18.6% of Solana shares are owned by institutional investors. 14.4% of Solana shares are owned by company insiders. Comparatively, 74.2% of QHSLab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Solana beats QHSLab on 8 of the 15 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About QHSLab

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.